NeuroVive Pharmaceutical AB Insider-Eigentum
Was ist das Insider-Eigentum von NeuroVive Pharmaceutical AB?
Insider-Eigentum von NeuroVive Pharmaceutical AB ist 17.55%
Was ist die Definition von Insider-Eigentum?
Das Insider-Eigentum wird berechnet als die Gesamtzahl der Aktien, die sich im Besitz von Insidern (Anteilseignern, die mehr als 5% der Gesellschaft oder eines leitenden Angestellten oder Direktors der Gesellschaft besitzen), dividiert durch die Gesamtzahl der ausstehenden Aktien.
A high value of insider ownership means that those working for the company have a large stake in the success of the company. This is sometimes seen as a sign that those running the company will work hard to ensure its success or believe the company's stock price will rise.
A change in insider ownership may come from exercise of option, stock grant and buying or selling of company shares. A purchase of company share signifies a confidence in the company's future performance by people who know the company best. Therefore, Net Insider buying is also an important indicator for investors.
Insider-Eigentum von Unternehmen in Miscellaneous Sektor auf LSE im Vergleich zu NeuroVive Pharmaceutical AB
Was macht NeuroVive Pharmaceutical AB?
Abliva AB (publ), a pharmaceutical company, engages in the research and development of mitochondrial medicine. The company is developing KL1333 that is in Phase I clinical trials for the chronic treatment of primary mitochondrial diseases; NV354, which is in the preparation for clinical trials for the treatment of primary mitochondrial diseases with Complex I deficiency; and NeuroSTAT for traumatic brain injury. It has collaboration agreements with Isomerase, Yungjin Pharm, University of Pennsylvania, Children's Hospital of Philadelphia, Patheon, and Oroboros Instruments. The company was formerly known as NeuroVive Pharmaceutical AB (publ) and changed its name to Abliva AB (publ) in May 2020. Abliva AB (publ) was incorporated in 2000 and is headquartered in Lund, Sweden.
Unternehmen mit insider-eigentum ähnlich NeuroVive Pharmaceutical AB
- Meteorite Capital hat Insider-Eigentum von 17.54%
- Distribution Finance Capital plc hat Insider-Eigentum von 17.54%
- Electro Optic Systems hat Insider-Eigentum von 17.55%
- Kuya Silver hat Insider-Eigentum von 17.55%
- Medgold Resources hat Insider-Eigentum von 17.55%
- HMN hat Insider-Eigentum von 17.55%
- NeuroVive Pharmaceutical AB hat Insider-Eigentum von 17.55%
- Ponce Inc hat Insider-Eigentum von 17.56%
- Valneva SE hat Insider-Eigentum von 17.57%
- Sichuan Expressway hat Insider-Eigentum von 17.57%
- Valneva SE hat Insider-Eigentum von 17.57%
- China Merchants Bank Co hat Insider-Eigentum von 17.57%
- Synaptogenix Inc hat Insider-Eigentum von 17.57%